 CAR T细胞实现连续杀伤的驱动因素 |
 |
|
每个 CAR T 细胞可以识别并溶解多个肿瘤细胞，是名副其实的连环杀手。
CAR T 细胞和其他细胞免疫疗法的临床效果取决于治疗产品的细胞溶解效力和代谢适应性。然而，人们对支持突触形成与迁移——驱动连续杀伤的两个关键因素——相关的能量代谢机制却知之甚少。 本次网络研讨会中，Roddy O’Connor 博士将讨论：
|
|
||||||
| 仅供科研使用，不用于临床诊断用途 | |||||
 | |||||
|
|
|
||||
|
Agilent Home • About Agilent • Legal • Subscriptions 5301 Stevens Creek Blvd, Santa Clara CA 95051, USA Agilent is committed to respecting and protecting your privacy. To view the promises that we make to you regarding your personal information, please view Agilent's privacy statement For questions related to privacy, please send your inquiry to privacy_advocate@agilent.com If you prefer not to receive promotional e-mails from Agilent in the future, you can unsubscribe at any time. You can also update your e-mail address, contact information, or interest profile to ensure you receive the most relevant information. © Agilent Technologies, Inc. 2023 |
|||||
